Effects of PA-1 Transcriptional Regulation on Monocyte Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00512369
Recruitment Status : Terminated (Investigator left institution)
First Posted : August 7, 2007
Last Update Posted : July 18, 2011
National Institutes of Health (NIH)
Information provided by:
Vanderbilt University

Brief Summary:
Researching genetic differences in people with no prior medical conditions for better understanding of cardiac diseases through genetic research.

Condition or disease

Detailed Description:
The discovery and subsequent application of small interfering RNA (siRNA) methods to achieve individual gene silencing in mammalian cells is a robust method that is well-described and validated in mammalian cell culture systems. We will apply this technique to achieve post-transcriptional "silencing" of PAI-1 in monocytes obtained from otherwise healthy volunteers, and study the subsequent loss of this gene's function on the migratory capacity of these cells in the proposed in vitro experimental system. This concept has not yet been demonstrated in the literature, and if validated, would be a novel and fundamental description of the role of PAI-1 in human monocyte biology as related to the development of atherosclerosis.

Study Type : Observational
Estimated Enrollment : 125 participants
Time Perspective: Prospective
Official Title: Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function
Study Start Date : March 2006
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Obese men and women

Inclusion Criteria:

  • Ages 18 -50
  • No current or past medical problems

Exclusion Criteria:

  • Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00512369

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
National Institutes of Health (NIH)
Principal Investigator: Mohan Sathyamoorthy, MD Vanderbilt University

Responsible Party: Douglas Vaughan, Vanderbilt University Identifier: NCT00512369     History of Changes
Other Study ID Numbers: 060286
First Posted: August 7, 2007    Key Record Dates
Last Update Posted: July 18, 2011
Last Verified: July 2011

Keywords provided by Vanderbilt University:
Metabolic pathways
Monocyte Function

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases